Drug intelligence / Profile preview

dexmedetomidine + propofol

Development stage
Unknown
Lead developer
Orion Pharma
Modality
Small Molecules
Administration
Intravenous
01

Overview

Dexmedetomidine + propofol is a combination of two intravenous sedative agents used primarily for procedural sedation, monitored anesthesia care, and intensive care unit (ICU) sedation. Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that provides sedative, anxiolytic, and mild analgesic effects without significant respiratory depression. Propofol is a short-acting hypnotic agent that acts as a positive allosteric modulator of the GABA-A receptor, producing rapid onset and offset of sedation or anesthesia. The combination leverages the complementary mechanisms of both drugs to achieve effective sedation with improved cardiovascular stability and reduced adverse effects compared to higher doses of either drug alone. Clinical studies have shown this combination can reduce the incidence of airway obstruction, hypoxia, agitation, and spontaneous movement while maintaining patient comfort and hemodynamic stability[1][4]. In critically ill patients requiring mechanical ventilation or deep sedation (such as in ICU settings), this regimen may allow for lower individual drug dosages and potentially fewer dose-related side effects[2][3].

Brand names
DiprivanPropovenPropofol-LipuroPropofolVet MultidosePropoFlo 28PropoFlo28PropoFlo-28CritifolAnefolAnepolAnesiaAnesproAnesvanAquafolB Braun PropofolBlofopDiprofenDiprofolDisoprivanFresofolGobbifolHiremonHospira PropofolInductofolIV-ProLe Wei JingPrecedexIgalmiDexdomitorSileo
Other names
milk of amnesiadexdor
02

Targets

ADRA2A (α2A)GABRR (GABA-A receptor subunit rho)

Beyond the preview

Go deeper on dexmedetomidine + propofol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dexmedetomidine + propofol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call